A
12.93
-0.19 (-1.45%)
| 前收盘价格 | 13.12 |
| 收盘价格 | 13.14 |
| 成交量 | 530,424 |
| 平均成交量 (3个月) | 1,936,322 |
| 市值 | 738,107,008 |
| 价格/销量 (P/S) | 1.04 |
| 股市价格/股市净资产 (P/B) | 5.22 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -1.88 |
| 总债务/股东权益 (D/E MRQ) | 1.75% |
| 流动比率 (MRQ) | 17.39 |
| 营业现金流 (OCF TTM) | -96.14 M |
| 杠杆自由现金流 (LFCF TTM) | -62.11 M |
| 资产报酬率 (ROA TTM) | -22.56% |
| 股东权益报酬率 (ROE TTM) | -32.89% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Astria Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.3
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.25 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.49% |
| 机构持股比例 | 106.43% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 49.00 (Cantor Fitzgerald, 278.96%) | 购买 |
| 中 | 16.50 (27.61%) | |
| 低 | 13.00 (Wedbush, 0.54%) | 保留 |
| 13.00 (Jefferies, 0.54%) | 保留 | |
| 平均值 | 23.75 (83.68%) | |
| 总计 | 2 购买, 2 保留 | |
| 平均价格@调整类型 | 9.58 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wedbush | 15 Oct 2025 | 13.00 (0.54%) | 保留 | 11.92 |
| Jefferies | 14 Oct 2025 | 13.00 (0.54%) | 保留 | 11.61 |
| Cantor Fitzgerald | 17 Sep 2025 | 49.00 (278.96%) | 购买 | 7.39 |
| HC Wainwright & Co. | 17 Sep 2025 | 20.00 (54.68%) | 购买 | 7.39 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合